FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157184585> ?p ?o ?g. }

• W3157184585 endingPage "562" @default.
• W3157184585 startingPage "550" @default.
• W3157184585 abstract "To assess the real-world healthcare resource utilization (HRU) and costs of patients with non-valvular atrial fibrillation (NVAF) and obesity newly initiated on rivaroxaban or warfarin in the US.This retrospective study used IQVIA PharMetrics Plus data (01/2010-09/2019) to evaluate patients (≥18 years) with NVAF and obesity (body mass index ≥30 kg/m2) initiated on rivaroxaban or warfarin (on or after 01/2013). Inverse probability of treatment weighting (IPTW) was used to adjust for confounding between cohorts. HRU and costs were assessed post-treatment initiation. Weighted cohorts were compared using Poisson regression models and cost differences, with 95% confidence intervals (CIs) and p values generated using non-parametric bootstrap procedures.After IPTW, 10,555 and 5,080 patients were initiated on rivaroxaban and warfarin, respectively (mean age: 59 years). At 12 months follow-up, the rivaroxaban cohort had lower all-cause HRU, including fewer hospitalizations (rate ratio [RR]: 0.80, 95% CI: 0.74, 0.87), emergency room visits (RR: 0.89, 95% CI: 0.83, 0.97), and outpatient visits (RR: 0.72, 95% CI: 0.69, 0.77; all p < .05). Medical costs were also reduced in the rivaroxaban cohort (mean difference: -$6,759, 95% CI: -$9,814, -$3,311) due to reduced hospitalization costs (mean difference: -$5,967, 95% CI: -$8,721, -$3,327), resulting in lower total all-cause healthcare costs compared to the warfarin cohort (mean difference: -$4,579, 95% CI: -$7,609, -$1,052; all p < .05). The rivaroxaban cohort also had lower NVAF-related HRU and medical costs driven by lower hospitalization at 12 months post-treatment initiation. HRU and cost reductions associated with rivaroxaban persisted up to 36 months of follow-up.Claims data may have contained inaccuracies and obesity was classified based on ICD diagnosis codes given that patient BMI values were not available.Rivaroxaban was associated with reduced HRU and costs compared to warfarin among NVAF patients with obesity in a real-world US setting." @default.
• W3157184585 created "2021-05-10" @default.
• W3157184585 creator A5003899519 @default.
• W3157184585 creator A5017834828 @default.
• W3157184585 creator A5019269759 @default.
• W3157184585 creator A5030107496 @default.
• W3157184585 creator A5047559786 @default.
• W3157184585 creator A5053327237 @default.
• W3157184585 creator A5076322910 @default.
• W3157184585 creator A5083841876 @default.
• W3157184585 date "2021-01-01" @default.
• W3157184585 modified "2023-09-24" @default.
• W3157184585 title "Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population" @default.
• W3157184585 cites W1008331282 @default.
• W3157184585 cites W1547546593 @default.
• W3157184585 cites W1572788090 @default.
• W3157184585 cites W1839975480 @default.
• W3157184585 cites W1964152230 @default.
• W3157184585 cites W1970194363 @default.
• W3157184585 cites W1971555447 @default.
• W3157184585 cites W2005891936 @default.
• W3157184585 cites W2016737319 @default.
• W3157184585 cites W2026341154 @default.
• W3157184585 cites W2028222171 @default.
• W3157184585 cites W2049491523 @default.
• W3157184585 cites W2056314295 @default.
• W3157184585 cites W2070350109 @default.
• W3157184585 cites W2073070194 @default.
• W3157184585 cites W2073780661 @default.
• W3157184585 cites W2074947904 @default.
• W3157184585 cites W2083713858 @default.
• W3157184585 cites W2096246254 @default.
• W3157184585 cites W2097854437 @default.
• W3157184585 cites W2103447466 @default.
• W3157184585 cites W2110818436 @default.
• W3157184585 cites W2114222699 @default.
• W3157184585 cites W2114775432 @default.
• W3157184585 cites W2115787552 @default.
• W3157184585 cites W2130199362 @default.
• W3157184585 cites W2130340163 @default.
• W3157184585 cites W2132505348 @default.
• W3157184585 cites W2136489990 @default.
• W3157184585 cites W2155779925 @default.
• W3157184585 cites W2160625453 @default.
• W3157184585 cites W2162508946 @default.
• W3157184585 cites W2166402206 @default.
• W3157184585 cites W2170350621 @default.
• W3157184585 cites W2176626491 @default.
• W3157184585 cites W2250684959 @default.
• W3157184585 cites W2311379003 @default.
• W3157184585 cites W2320150589 @default.
• W3157184585 cites W2335906448 @default.
• W3157184585 cites W2547585100 @default.
• W3157184585 cites W2597608277 @default.
• W3157184585 cites W2734888494 @default.
• W3157184585 cites W2761300892 @default.
• W3157184585 cites W2793693414 @default.
• W3157184585 cites W2800220890 @default.
• W3157184585 cites W2884200680 @default.
• W3157184585 cites W2888594054 @default.
• W3157184585 cites W2917417270 @default.
• W3157184585 cites W2946668006 @default.
• W3157184585 cites W2976287518 @default.
• W3157184585 cites W2986934488 @default.
• W3157184585 cites W2991063051 @default.
• W3157184585 cites W3020538686 @default.
• W3157184585 cites W3190351271 @default.
• W3157184585 cites W4243445701 @default.
• W3157184585 doi "https://doi.org/10.1080/13696998.2021.1915627" @default.
• W3157184585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33910464" @default.
• W3157184585 hasPublicationYear "2021" @default.
• W3157184585 type Work @default.
• W3157184585 sameAs 3157184585 @default.
• W3157184585 citedByCount "3" @default.
• W3157184585 countsByYear W31571845852021 @default.
• W3157184585 countsByYear W31571845852023 @default.
• W3157184585 crossrefType "journal-article" @default.
• W3157184585 hasAuthorship W3157184585A5003899519 @default.
• W3157184585 hasAuthorship W3157184585A5017834828 @default.
• W3157184585 hasAuthorship W3157184585A5019269759 @default.
• W3157184585 hasAuthorship W3157184585A5030107496 @default.
• W3157184585 hasAuthorship W3157184585A5047559786 @default.
• W3157184585 hasAuthorship W3157184585A5053327237 @default.
• W3157184585 hasAuthorship W3157184585A5076322910 @default.
• W3157184585 hasAuthorship W3157184585A5083841876 @default.
• W3157184585 hasBestOaLocation W31571845851 @default.
• W3157184585 hasConcept C126322002 @default.
• W3157184585 hasConcept C167135981 @default.
• W3157184585 hasConcept C194828623 @default.
• W3157184585 hasConcept C2776301958 @default.
• W3157184585 hasConcept C2778661090 @default.
• W3157184585 hasConcept C2779161974 @default.
• W3157184585 hasConcept C2780221984 @default.
• W3157184585 hasConcept C2908647359 @default.
• W3157184585 hasConcept C71924100 @default.
• W3157184585 hasConcept C72563966 @default.
• W3157184585 hasConcept C99454951 @default.
• W3157184585 hasConceptScore W3157184585C126322002 @default.

• next